Enhancement of the response of B16F1 melanoma to fractionated radiotherapy and prolongation of survival by withaferin A and/or hyperthermia.
Withaferin A (WA), isolated from Indian medicinal plant Withania somnifera has weak antitumor and radiosensitizing property. The present investigation was planned to evaluate the tumor sensitizing effect of WA with or without local hyperthermia on the response of B16F1 melanoma to fractionated and acute radiotherapy. C57BL mice bearing tumors of 100 ± 10 mm³ were treated with fractionated radiotherapy (RT, 2 Gy x 5 days/week, 4 weeks), withaferin A (15 mg/kg, i.p., 5 days/ week, 3 weeks), local hyperthermia (HT, 43°C once a week, 3 weeks) and their combinations, or acute RT (40 Gy), WA (40 mg/kg), HT (43°C, 30 min) and their combinations. Treatment response was studied by tumor regression, growth delay and animal survival. Acute RT+HT produced 50% partial response which increased to 62.5% with combination of WA. In fractionated regimen, trimodality combination resulted in 100% PR. Acute RT+HT and WA+RT produced similar increase in growth delay (GD) compared to RT alone which further increased in trimodality treatment. Fractionated WA+RT+HT for 3 weeks produced a higher GD and survival than all other treatments. In conclusion, WA is a better radiosensitizer than HT in fractionated regimen and the response of radioresistant tumors like melanoma can be significantly enhanced by combining nontoxic doses of WA with fractionated RT, with or without HT, allowing decrease in radiation dose.
Kalthur
Guruprasad
G
Manipal University, Manipal, Karnakata, India. guru.kalthur@manipal.edu
Pathirissery
Uma Devi
UD
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D006979:Hyperthermia, Induced; D008546:Melanoma, Experimental / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D018714:Radiotherapy, Adjuvant / Q000379:methods*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome; D054358:Withanolides / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D054358:Withanolides; C009684:withaferin A